Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 8/20 | 0.49 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 3/20 | 0.43 |
| ▸ | HTR7 | P34969 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239264 | 1.00 | DPP4 (0.49) | DPP4ACEHTR1AHTR7ALDH1A1 | |
| SCHEMBL3396586 | 1.00 | DPP4 (0.49) | DPP4ACEHTR1AHTR7ALDH1A1 | |
| SCHEMBL22481429 | 0.95 | DPP4 (0.45) | DPP4ACEHTR1AHTR7 | |
| SCHEMBL6168040 | 0.89 | ALDH1A1 (0.41) | DPP4HTR1AHTR7ALDH1A1LMNA | |
| SCHEMBL8772871 | 0.83 | DPP4 (0.56) | DPP4ACEHTR1AHTR7 | |
| SCHEMBL1170836 | 0.83 | ACE (0.62) | ACELMNA | |
| SCHEMBL1493753 | 0.83 | DPP4 (0.47) | DPP4ACEHTR1AHTR7 | |
| SCHEMBL20839701 | 0.83 | ACE (0.62) | ACELMNA | |
| SCHEMBL8772866 | 0.83 | DPP4 (0.56) | DPP4ACEHTR1AHTR7 | |
| SCHEMBL3200494 | 0.83 | ACE (0.62) | ACELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114441657-A | Method for detecting vildagliptin genotoxic impurities | 康普药业股份有限公司 | 2022-05-06 | — | — | CN | claimed |
| WO-2011101861-A1 | PROCESS FOR PREPARATION OF DPP-IV INHIBITORS | MSN LABORATORIES LIMITED (IN) | 2011-08-25 | — | — | WO | claimed |
| WO-2011012322-A9 | SYNTHESIS AND USE OF VILDAGLIPTIN FOR THE PREPARATION OF PHARMACEUTICAL DOSAGE FORMS | KRKA, D.D., NOVO MESTO (SI) | 2011-08-11 | — | — | WO | claimed |
| CN-113264863-B | Preparation method of (S) -1- (2-chloroacetyl) pyrrolidine-2-carbonitrile with high chiral purity | 合肥利夫生物科技有限公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118619868-A | Preparation method of deuterated vildagliptin bulk drug | 山东丰金制药有限公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-115650984-A | Preparation method of anagliptin | 江苏君若药业有限公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115586276-A | Method for detecting genotoxic impurities of vildagliptin | 海南通用三洋药业有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-112028806-B | Synthetic method of vildagliptin intermediate | 河北合佳医药科技集团股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114441657-A | Method for detecting vildagliptin genotoxic impurities | 康普药业股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-114441657-A | Method for detecting vildagliptin genotoxic impurities | 康普药业股份有限公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-110642769-B | Preparation method of vildagliptin | 烟台万润药业有限公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2010017418-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010017418-A1 | PRODRUGS OF FUSED HETEROCYCLIC INHIBITORS OF D-AMINO ACID OXIDASE | SEPRACOR INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| EP-1888571-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. Hoffmann-Roche AG (CH) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006100181-A2 | NEW SALT AND POLYMORPHS OF A DPP-IV INHIBITOR | F. HOFFMANN-LA ROCHE AG (CH) | 2006-09-28 | — | — | WO | disclosed |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | HOFFMANN-LA ROCHE INC. | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | PPARG, PPARA, PPARD | DPP4 765/4885ACE 1985/4885HTR1A 3250/4885 |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | PPARG, PPARA, PPARD | DPP4 200/4885ACE 423/4885HTR1A 2251/4885 |
| US-20060217428-A1 | Salt and polymorphs of a DPPIV inhibitor | DPP4, DPP3, DPP9 | DPP4 1/4885ACE 28/4885HTR1A 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.